<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04155281</url>
  </required_header>
  <id_info>
    <org_study_id>38RC19.214</org_study_id>
    <secondary_id>2019-A02214-53</secondary_id>
    <nct_id>NCT04155281</nct_id>
  </id_info>
  <brief_title>New Psychoactive Substances in Intoxicated Patients During the Winter Activities</brief_title>
  <acronym>SKI-Tox</acronym>
  <official_title>Consumption of New Psychoactive Substances in Intoxicated Patients During the Winter Activities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to identify the New Psychoactive Substances (NPS) that are
      responsible for intoxicating patients in ski resort during winter activities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The New Psychoactive Substances expose to an additional risk of overdose or death due to
      their potency. These New Psychoactive Substances are used voluntarily by users wishing to
      test new substances, but also involuntarily because of association (unknowingly users) with
      more &quot;conventional&quot; drugs such as cocaine or heroin in the self-administered powder. These
      intoxications are still poorly known and the investigators believe that the identification of
      New Psychoactive Substances among the drugs consumed, and the association of their
      consumption with the appearance of a particular symptomatology allow the physician to guide
      the diagnosis and facilitate the care of future patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>positive urinary sample</measure>
    <time_frame>Day 0</time_frame>
    <description>proportion of urine samples positive for New Psychoactive Substances and related, among patients suspected of intoxication and from a ski resort, in winter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of toxidromes</measure>
    <time_frame>baseline</time_frame>
    <description>Clinical symptoms observed in intoxicated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>polyintoxication frequency</measure>
    <time_frame>baseline</time_frame>
    <description>Percentage of co-intoxications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>morbidity of intoxication</measure>
    <time_frame>baseline and month 1</time_frame>
    <description>length of stay in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>morbidity of intoxication</measure>
    <time_frame>baseline and month 1</time_frame>
    <description>Percentage of Intensive Care Unit admissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of intoxication medical care</measure>
    <time_frame>day 1</time_frame>
    <description>names of therapies implemented within 24 hours of admission</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Intoxication</condition>
  <condition>Psychoactive Substance Use</condition>
  <arm_group>
    <arm_group_label>suspicion of intoxication</arm_group_label>
    <description>New Psychoactive Substances research in urine</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>urine analysis</intervention_name>
    <description>New Psychoactive Substances research in urine at admission in unit care</description>
    <arm_group_label>suspicion of intoxication</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patient will be included at admission to hospital. After recording non-opposition to the
        study, the urinary sample of the medical care will be kept and send to the central lab for
        analysis and new psychoactive substances research.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission to emergency, resuscitation or intensive care departments involved in the
             study

          -  Anamnestic and / or clinical suspicion of acute drug poisoning according to
             International Classification of Diseases-10 criteria

          -  Patient coming from a ski resort from the pre-established list

          -  urine sample available as part of the treatment

          -  person understanding French or English

          -  Non-opposition to the study

        Exclusion Criteria:

          -  Suspicion of alcohol intoxication alone

          -  Suspicion of voluntary drug poisoning

          -  Suspicion of intentional intoxication by others

          -  Pregnant or lactating women

          -  Major mentioned in Articles L1121-6 and 1121-8 of french public health code

          -  Patients in the exclusion period of another research involving the human person type 1
             or 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maxime Maignan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michel Mallaret, MD</last_name>
    <phone>+334 76 76 51 45</phone>
    <email>mmallaret@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roseline Collomb-Muret</last_name>
    <phone>+334 76 76 76 92</phone>
    <email>rcollombmuret@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Albertville Moutiers</name>
      <address>
        <city>Albertville</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Damien Venchiarutti, MD</last_name>
      <phone>+33479895522</phone>
      <email>damien.venchiarutti@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Damien Venchiarutti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxime Maignan, MD,PhD</last_name>
      <email>mmaignan@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Roseline Collomb-Muret</last_name>
      <email>rcollombmuret@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Maxime Maignan, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Terzi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damien Viglino, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Rivera JV, Vance EG, Rushton WF, Arnold JK. Novel Psychoactive Substances and Trends of Abuse. Crit Care Nurs Q. 2017 Oct/Dec;40(4):374-382. doi: 10.1097/CNQ.0000000000000174. Review.</citation>
    <PMID>28834859</PMID>
  </reference>
  <reference>
    <citation>Yang F-S, Chen C-J, Lin Y-C. &quot;Zombie&quot; Outbreak Caused by Synthetic Cannabinoid. N Engl J Med. 2017 Apr 20;376(16):1596-7. doi: 10.1056/NEJMc1701936.</citation>
    <PMID>28425277</PMID>
  </reference>
  <reference>
    <citation>Frank RG, Pollack HA. Addressing the Fentanyl Threat to Public Health. N Engl J Med. 2017 Feb 16;376(7):605-607. doi: 10.1056/NEJMp1615145.</citation>
    <PMID>28199808</PMID>
  </reference>
  <reference>
    <citation>Khaled SM, Hughes E, Bressington D, Zolezzi M, Radwan A, Badnapurkar A, Gray R. The prevalence of novel psychoactive substances (NPS) use in non-clinical populations: a systematic review protocol. Syst Rev. 2016 Nov 21;5(1):195.</citation>
    <PMID>27871332</PMID>
  </reference>
  <reference>
    <citation>Kunst LE, Gebhardt WA. Prevalence and Psychosocial Correlates of Party-Drug Use and Associated Problems among University Students in the Netherlands. Subst Use Misuse. 2018 Oct 15;53(12):2077-2088. doi: 10.1080/10826084.2018.1455700. Epub 2018 Apr 18.</citation>
    <PMID>29668345</PMID>
  </reference>
  <reference>
    <citation>Palamar JJ, Barratt MJ, Ferris JA, Winstock AR. Correlates of new psychoactive substance use among a self-selected sample of nightclub attendees in the United States. Am J Addict. 2016 Aug;25(5):400-7. doi: 10.1111/ajad.12403. Epub 2016 Jul 15.</citation>
    <PMID>27419383</PMID>
  </reference>
  <reference>
    <citation>Ridpath A, Driver CR, Nolan ML, Karpati A, Kass D, Paone D, Jakubowski A, Hoffman RS, Nelson LS, Kunins HV; Centers for Disease Control and Prevention (CDC). Illnesses and deaths among persons attending an electronic dance-music festival - New York City, 2013. MMWR Morb Mortal Wkly Rep. 2014 Dec 19;63(50):1195-8.</citation>
    <PMID>25522087</PMID>
  </reference>
  <reference>
    <citation>Fox J, Smith A, Yale A, Chow C, Alaswad E, Cushing T, Monte AA. Drugs of Abuse and Novel Psychoactive Substances at Outdoor Music Festivals in Colorado. Subst Use Misuse. 2018 Jun 7;53(7):1203-1211. doi: 10.1080/10826084.2017.1400067. Epub 2017 Nov 17.</citation>
    <PMID>29148866</PMID>
  </reference>
  <reference>
    <citation>Liakoni E, Dolder PC, Rentsch KM, Liechti ME. Presentations due to acute toxicity of psychoactive substances in an urban emergency department in Switzerland: a case series. BMC Pharmacol Toxicol. 2016 May 26;17(1):25. doi: 10.1186/s40360-016-0068-7.</citation>
    <PMID>27228985</PMID>
  </reference>
  <reference>
    <citation>Palamar JJ, Salomone A, Gerace E, Di Corcia D, Vincenti M, Cleland CM. Hair testing to assess both known and unknown use of drugs amongst ecstasy users in the electronic dance music scene. Int J Drug Policy. 2017 Oct;48:91-98. doi: 10.1016/j.drugpo.2017.07.010. Epub 2017 Aug 12.</citation>
    <PMID>28810159</PMID>
  </reference>
  <reference>
    <citation>Miliano C, Margiani G, Fattore L, De Luca MA. Sales and Advertising Channels of New Psychoactive Substances (NPS): Internet, Social Networks, and Smartphone Apps. Brain Sci. 2018 Jun 29;8(7). pii: E123. doi: 10.3390/brainsci8070123. Review.</citation>
    <PMID>29966280</PMID>
  </reference>
  <reference>
    <citation>Robach P, Trebes G, Lasne F, Buisson C, Méchin N, Mazzarino M, de la Torre X, Roustit M, Kérivel P, Botré F, Bouzat P. Drug Use on Mont Blanc: A Study Using Automated Urine Collection. PLoS One. 2016 Jun 2;11(6):e0156786. doi: 10.1371/journal.pone.0156786. eCollection 2016.</citation>
    <PMID>27253728</PMID>
  </reference>
  <reference>
    <citation>Orsini J, Din N, Elahi E, Gomez A, Rajayer S, Malik R, Jean E. Clinical and epidemiological characteristics of patients with acute drug intoxication admitted to ICU. J Community Hosp Intern Med Perspect. 2017 Sep 19;7(4):202-207. doi: 10.1080/20009666.2017.1356189. eCollection 2017 Oct.</citation>
    <PMID>29046744</PMID>
  </reference>
  <reference>
    <citation>Helander A, Bäckberg M, Hultén P, Al-Saffar Y, Beck O. Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project. Forensic Sci Int. 2014 Oct;243:23-9. doi: 10.1016/j.forsciint.2014.02.022. Epub 2014 Mar 6.</citation>
    <PMID>24726531</PMID>
  </reference>
  <reference>
    <citation>Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of &quot;bath salts&quot; and &quot;legal highs&quot; (synthetic cathinones) in the United States. Clin Toxicol (Phila). 2011 Jul;49(6):499-505. doi: 10.3109/15563650.2011.590812.</citation>
    <PMID>21824061</PMID>
  </reference>
  <reference>
    <citation>Beck O, Franzén L, Bäckberg M, Signell P, Helander A. Toxicity evaluation of α-pyrrolidinovalerophenone (α-PVP): results from intoxication cases within the STRIDA project. Clin Toxicol (Phila). 2016 Aug;54(7):568-75. doi: 10.1080/15563650.2016.1190979.</citation>
    <PMID>27412885</PMID>
  </reference>
  <reference>
    <citation>Bäckberg M, Beck O, Hultén P, Rosengren-Holmberg J, Helander A. Intoxications of the new psychoactive substance 5-(2-aminopropyl)indole (5-IT): a case series from the Swedish STRIDA project. Clin Toxicol (Phila). 2014 Jul;52(6):618-24. doi: 10.3109/15563650.2014.920088. Epub 2014 Jun 4.</citation>
    <PMID>24895941</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 27, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

